Developing a new test to measure drug resistance in hepatitis C virus
Next generation quantitative HCV drug resistance assay
This study is working on a new test that helps doctors find out if the hepatitis C virus in patients has changed in a way that makes it resistant to treatments, so they can choose the best medicine for people who haven't had success with previous therapies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medosome Biotec, LLC NIH-funded |
| Lab location | 1 site (Alachua, UNITED STATES) |
| Project ID | NIH-10453759 on NIH RePORTER |
What this research studies
This research focuses on creating a next-generation assay that can accurately measure the presence and linkage of hepatitis C virus (HCV) variants that are resistant to antiviral treatments. By identifying resistance-associated substitutions (RASs) in patients, the assay aims to improve treatment outcomes for individuals infected with HCV. The methodology involves advanced sequencing technology to provide precise data on drug resistance, which can guide healthcare providers in selecting the most effective treatment regimens for patients. This approach is particularly important for those who have previously failed antiviral therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with hepatitis C, especially those who have not responded to previous antiviral treatments.
Not a fit: Patients who are not infected with hepatitis C or those who have not undergone antiviral treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for hepatitis C, improving the chances of achieving sustained virologic response in patients.
How similar studies have performed: Previous research has shown promise in developing assays for drug resistance in other viral infections, indicating potential success for this novel approach in hepatitis C.
Where this research is happening
Alachua, UNITED STATES
- Medosome Biotec, LLC — Alachua, United States (Active)
Researchers
- Principal investigator: Wagner, Richard — Medosome Biotec, LLC
- Study coordinator: Wagner, Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.